Company intelligence / Profile preview

Akers Biosciences

Thorofare, New Jersey, United Statestnfpharma.com ↗

Ownership: Private
Employees: ~13
Development stage: Other

Overview

Akers Biosciences developed and commercialized rapid point-of-care diagnostic tests for a range of indications including heparin allergy detection and breath-based wellness markers. The company’s platform technologies enabled quick results in minutes at the point-of-care or home setting. No ongoing clinical trials or new drug candidates were reported at the time of its merger with MyMD Pharmaceuticals[2][3][5].

Therapeutic areas: Metabolic DisordersPsychiatryHematologyOtherCardiovascular
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

Major healthcare companies and high-volume medical product distributors for global distribution[2].

Beyond the preview

Go deeper on Akers Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Akers Biosciences.

Explore the full profile